Dr. Reddy's Laboratories is a major Indian pharmaceutical company founded in 1984 and headquartered in Hyderabad. It has over 190 medications and 60 active pharmaceutical ingredients. The company has a global workforce of over 20,000 employees and a commercial presence in 26 countries. Dr. Reddy's Laboratories aims to bring new medicines to India at affordable prices. It has several subsidiaries and joint ventures around the world. The company produces generic medicines, APIs, differentiated formulations, and biosimilars. Its major competitors include Sun Pharma, Lupin, Aurobindo Pharma, and Cipla.
Cipla Limited is an Indian multinational pharmaceutical company, headquartered in Mumbai, India. Cipla primarily develops medicines to treat respiratory, cardiovascular disease, arthritis, diabetes, weight control and depression; other medical conditions.
Cipla Limited is an Indian multinational pharmaceutical company, headquartered in Mumbai, India. Cipla primarily develops medicines to treat respiratory, cardiovascular disease, arthritis, diabetes, weight control and depression; other medical conditions.
PPt on Product Mix of HUl
Introduction
Product mix of hul and Bru Coffee
their width,length,depth,consistenct in detail
Bru coffee product and their categorization in detail
PPt on Product Mix of HUl
Introduction
Product mix of hul and Bru Coffee
their width,length,depth,consistenct in detail
Bru coffee product and their categorization in detail
Mintop - Hairfall Treatment by Dr. Reddy’s LaboratoriesShailaja Rao
Mintop by Dr.Reddy’s Labs is a scientifically proven treatment for hair loss curing baldness and helping in re-growth of the lost hair in both men and women.
Visit:http://www.mintop.in/
Aalysis of Dr.reddys laboratory stock
Brief description about the company and then going to ratio analysis and then technical analysis was made.
Different technical indicators were discussed and some snapshots of plots obtained from etcharts were also attached which provides easy understanding.
So after reading this we can decide on whether to buy or sell the security or a commodity
TetraQ - Integrated Preclinical Drug Development Solutions Presentationguest55305
TetraQ is a leading Australian preclinical contract research organization focused on providing a broad range of integrated preclinical drug development solutions in the disciplines of ADME, Bioanalytics, Efficacy, Toxicology and Pharmaceutics. TetraQ’s Toxicology, ADME and Bioanalytics laboratories are GLP recognised and in collaboration with NATA, TetraQ’s ADME team pioneered ISO17025-2005 (R&D) research & development accreditation becoming the first laboratory in Australia to obtain this accreditation in 2005.
Each of our world-class facilities is equipped with state-of-the-art instrumentation including LC-MS/MS, HPLC & ELISA. Essentially, TetraQ is a one-stop-shop for early stage drug development and we are recognized as world leaders in bioanalytical method development & sample analysis of drugs / metabolites in biological fluids with both human and animal samples.
For many, hair loss can be a devastating psychological condition. Unfortunately, dermatologists and primary doctors often fall short when it comes to the state-of-the-art diagnosis and treatment. It's up to hair restoration physicians and integrative practices to take the lead in the medical management of hair loss. Helping patients maintain, enhance and restore their own living and growing hair is a rewarding field to be in. Mismanaging patients expectations or therapies will certainly lead to disappointment. In this webinar, learn an overview of how we diagnose, measure, treat and track hair loss patients on various effective medical regimens. We often prescribe finasteride and FinPlus compounded finasteride, Formula82M minoxidil, LaserCap and in-office laser therapy, PRP with ECM BioD ACell, nutraceuticals and FUE NeoGraft hair transplantation. See some before and afters from various monotherapy patients. HairCheck cross sectional hair bundle trichometry is the key to keeping patients compliant. Thank you to LaserCap
Additional training is available from Dr. Alan J Bauman so visit http://www.haircoach.net for upcoming hands-on PRP and HairCheck classes.
MP Advisors is a Consultancy firm with an exclusive focus on Pharmaceuticals / Biotechnology sectors in the US, Europe, India, Japan and Russia. It was operating earlier as an international affiliate of Mehta Partners LLC since 1996. Today it has a highly motivated, qualified team of PhD's, MBA's and Pharmacist who apply their domain knowledge to develop proprietary data bases, understand dynamic regulatory laws across geographies, track and analyze latest trends in drug development, clinical trials and specific diseases. MP Advisors has insightful information on more than 200 pharma and Biotech companies around the globe as well as publishes reports on Key Opinion Leaders (Physician’s view) assessment, therapy class review of several classes (e.g. Oral anticoagulants, Hepatitis C, Obesity, Novel Drug Delivery systems, Biosimilars etc.), India and Japan generic opportunities and Paragraph IV Opportunities.
This report is based on the summer training undertaken with lupin ltd anleshwar. It will be beneficial to the students who appear for training with lupin ankleshwar. The report also contains mini project on job rotation and transfer.
Pharmaceuticals Industry Analysis with analysis of Top notch Companies in pharmaceuticals viz. Sun pharma, Lupin, Dr. Reddy's Laboratory, Cipla, Aurobindo Pharma to identify opportunity to invest in equity share of these companies.
Indian companies are taking center stage in Complex Generics at US and EU mar...mpadvisors
Key Topics Covered
1. Uniform Code on Sales and Marketing Practices in India
2. Issuance of warning letters to Indian facilities by USFDA: not a concern
3. Biosimilar perspective for Indian market
4. New drug discovery development in India
5. Biocon: Sits comfortable with its near and long term contributory products
6. Cadila Healthcare: NCE, Transdermal, Biosimilars and Complex generics launches thru 2016 –Eventful time ahead
7. Cipla: Major change in business model
8. Dr. Reddy’s Lab: Focus on Complex formulations and Biogenerics to intensify
9. Glenmark: US business, NCE and ParaIV will show significant growth
10. IPCA: Fine chemicals to formulation –Global leadership in select products
11. Lupin: US and Japan Business –Key for long term growth
12. Natco: Leveraging chemistry, formulation and IP strength –For Us and India Markets
13. Panacea Biotec: Financial trouble mounting, Acceptance of WHO prequalification and formulation business will revive the company
14. Shasun: On path to become fully integrated Pharma company
15. Shilpa Medicare: A leader in Oncology API, Expanding into Non-Onco, peptides and complex formulations
16. Sun Pharma: Strong Management Team - Absolute and Comparative Advantage
2. Dr Reddy’s Laboratories
The Home-grown Pharmaceutical Giant
Company Based Research
Presentation
MANASH PRATIM KALITA
ROLL NO-198
SECTION-M4
3. Introduction
Dr.Reddy’s laboratories is a premier and major Indian pharmaceutical
company headquartered in hyderabad
Founded by Kallam Anji Reddy in 1984
Over 190 medications, 60 active pharmaceutical ingredients(api) for drug
manufacture, diagnostic kits and critical care units
To bring new molecules into the country at a price the common man can afford
Global workforce-20000+
Commercial presence-26 countries
1/4/2017Manash Pratim Kalita,Roll No-198,Section-M4
4. Group Companies
Dr. Reddy's laboratories Australia pvt ltd, a wholly owned subsidiary of dr.
Reddy's laboratories ltd
In china joint venture with Rotam group
Dr. Reddy's operates in Germany through its subsidiary Betapharm
Dr. Reddy’s laboratories ltd. decided to enter the market directly through a
joint venture with Venturepharm
Dr. Reddy’s laboratories UK ltd was created with the acquisition of BMS
laboratories and its subsidiary meridian healthcare
1/4/2017Manash Pratim Kalita,Roll No-198,Section-M4
5. Goal
Good health
Commitment
That’s why the company believes in “Good health cant wait”
Principles
Empathy and Dynamism
Purpose
We accelerate access to affordable and innovative medicines because good
health cant wait
1/4/2017Manash Pratim Kalita,Roll No-198,Section-M4
6. Hierarchy and Organizational
Structure
CHAIRMAN
COO
GLOBAL HR
HEAD
EVP CFO
CO-CHAIRMAN
CUM CEO
Whole time directors
Satish Reddy
G V Prasad
Independent and non-whole time directors
Dr.Omkar Goswami
Anupam Puri
Kalpana Morparia
Dr. Bruce LA Carter
1/4/2017Manash Pratim Kalita,Roll No-198,Section-M4
7. Products and Services
GENERICS- Omez (Omeprazole), Nise (Nimesulide),Ketorol
(Ketorolac Thromethamine), Stamlo (Amlodipine Besylate), Razo
(Rabeprazole)
OVER THE COUNTER- Cetrine, Nise gel, Ibuclin and Novigan.US nicotine
replacement therapy transdermal patch named Habitrol.
API(ACTIVE PHARMACEUTICAL INGREDIENTS)- caters to leading
innovator and generic companies across the US, Europe, Latin America, Japan,
Korea and other emerging markets such as steroids, peptides, complex long
chain synthesis and oncology
BIOLOGICS- Biologics – large molecule protein therapies – for an effective
treatment that may have fewer side effects.
DIFFERENTIATED FORMULATIONS- Custom Pharma Services (CPS)
1/4/2017Manash Pratim Kalita,Roll No-198,Section-M4
8. Major Competitors of the Company
Sun Pharma
Lupin
Aurobindo Pharma
Cipla
Cadila
Ranbaxy Labs
Divis labs
International Competitors
Abbot Laboratories
Abeona Therapeutics
1/4/2017Manash Pratim Kalita,Roll No-198,Section-M4
9. NAME
SALES
TURNOVER
MARKET SHARE IN
%
Sun Pharma 7,614.46 8.137796832
Lupin 11,239.80 12.01230407
Dr Reddys Labs 10,207.70 10.90926851
Aurobindo Pharm 9,166.18 9.796165527
Cipla 12,034.06 12.86115303
Cadila Health 7,035.30 7.518831545
Ranbaxy Labs 6,864.94 7.336762815
Divis Labs 3,721.33 3.977094565
Piramal Enter 3,516.53 3.758218796
GlaxoSmithKline 2,826.21 3.020453556
Torrent Pharma 5,429.00 5.802131602
Glenmark 6,113.50 6.533676837
Alkem Lab 3,924.69 4.194431364
Biocon 2,323.60 2.483299501
Ajanta Pharma 1,551.76 1.658411445
TOTAL 93,569.06 100
8.137796832
12.01230407
10.90926851
9.796165527
12.86115303
7.518831545
7.336762815
3.977094565
3.758218796
3.020453556
5.802131602
6.533676837
4.194431364 2.483299501
1.658411445
MARKET SHARE IN %
Sun Pharma Lupin Dr Reddys Labs Aurobindo Pharm
Cipla Cadila Health Ranbaxy Labs Divis Labs
Piramal Enter GlaxoSmithKline Torrent Pharma Glenmark
Alkem Lab Biocon Ajanta Pharma
Market Share
1/4/2017Manash Pratim Kalita,Roll No-198,Section-M4
10. Ownership
PARTICULARS % OF SHARES
Promoter(individual and companies) 26.37
Indian financial institutions 2.83
Banks 0.15
Mutual funds 2.76
FIIs 35.41
NRIs 1.25
Foreign Companies 2.98
Indian Public 11.40
1/4/2017Manash Pratim Kalita,Roll No-198,Section-M4
11. Strength
1.Low cost chemotherapy medicine
2.Proprietary chiral and
biocatalysis know-how
3.Betapharma acquisition gives
access to European markets
Weakness
1.Government regulations and
national drug policy
2.Huge investment
3.Highly unpredictable sector
Opportunities
1.Oncology market entry
2.Partnership in bio-similar markets
3.Cost effective methodologies in
emerging markets
Threats
1.Preliminary investment very high
2.Patents
3.Foreign giant entry
1/4/2017Manash Pratim Kalita,Roll No-198,Section-M4
14. CSR Expenditure
2016---3.04%
2014-15---1.74%
2013-14---1.03%
2012-13---1.33%
CSR provisions in Companies Act,2013
every company, private limited or public limited, which either has a net worth of Rs 500 crore or a
turnover of Rs 1,000 crore or net profit of Rs 5 crore, needs to spend at least 2% of its average net
profit for the immediately preceding three financial years on corporate social responsibility
activities
1/4/2017Manash Pratim Kalita,Roll No-198,Section-M4
16. Economic Analysis
High economies of scale
Low cost products so tough entry for players
Extensive R&D hence no threats from patent expiration
Alliances, joint ventures or acquisition
Easing of norms under “Make in India” programme
1/4/2017Manash Pratim Kalita,Roll No-198,Section-M4
17. Conclusion
Made healthcare more affordable
Giant Indian player in US, Russia and CIS countries
FDA regulations getting tougher
Currently focus is not only on foreign countries but also in India
NYSE listed company
1/4/2017Manash Pratim Kalita,Roll No-198,Section-M4